BENZYLDIMETHYL(2-(2-((4-(1,1,3,3-TETRAMETHYLBUTYL)-M-TOLYL)OXY)ETHOXY)ETHYL)AMMONIUM CHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C28H44NO2.Cl
Molecular Weight	462.107
Optical Activity	NONE
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of BENZYLDIMETHYL(2-(2-((4-(1,1,3,3-TETRAMETHYLBUTYL)-M-TOLYL)OXY)ETHOXY)ETHYL)AMMONIUM CHLORIDE

Structure Search

SMILES

[Cl-].CC1=CC(OCCOCC[N+](C)(C)CC2=CC=CC=C2)=CC=C1C(C)(C)CC(C)(C)C

InChI

InChIKey=WYWSKWZUWZLELX-UHFFFAOYSA-M

InChI=1S/C28H44NO2.ClH/c1-23-20-25(14-15-26(23)28(5,6)22-27(2,3)4)31-19-18-30-17-16-29(7,8)21-24-12-10-9-11-13-24;/h9-15,20H,16-19,21-22H2,1-8H3;1H/q+1;/p-1

HIDE SMILES / InChI

Description
Sources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Rishum_2_276001616.pdf | https://www.ncbi.nlm.nih.gov/pubmed/17306255

Methylbenzethonium chloride is a quaternary ammonium with antimicrobial activity, which is used in combination with aminoglycoside antibiotic, paromomycin (brand name LESHCUTAN) for the topical treatment of cutaneous leishmaniasis.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Cutaneous leishmaniasis 4 Sources: https://www.old.health.gov.il/units/pharmacy/trufot/alonim/Rishum_2_276001616.pdf	Curative		Approved 8583	LESHCUTAN Approved Use Unknown

PubMed

Title	Date	PubMed
Leishmania major: in vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod.	2007-06	17306255
Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala.	2001-11	11716099
Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment of American cutaneous leishmaniasis: controlled study.	1999-08	10476776

Patents

Sample Use Guides

In Vivo Use Guide

1- Clean the affected area and completely cover with the ointment. A sterile dressing can be used to dress the area. 2- Apply the ointment twice a day, for about 10 days. If full recovery is not achieved, the doctor will consider administration of an additional 10-day course of treatment.

Route of Administration: Topical

In Vitro Use Guide

Methylbenzethonium chloride at 0.1 and 0.5 microg/ml inhibited the parasite development by 39.5% and 65.2%. Imiquimod (5-10 microg/ml) combined with either paromomycin (25, 50 and 100 microg/ml) or methylbenzethonium chloride (0.1 and 0.5 microg/ml) showed an anti-leishmanial additive effect.

Name

Type

Language

AMMONIUM, BENZYLDIMETHYL(2-(2-((4-(1,1,3,3-TETRAMETHYLBUTYL)-M-TOLYL)OXY)ETHOXY)ETHYL)-, CHLORIDE

Preferred Name

English

BENZYLDIMETHYL(2-(2-((4-(1,1,3,3-TETRAMETHYLBUTYL)-M-TOLYL)OXY)ETHOXY)ETHYL)AMMONIUM CHLORIDE

Systematic Name

English

BENZENEMETHANAMINIUM, N,N-DIMETHYL-N-(2-(2-(3-METHYL-4-(1,1,3,3-TETRAMETHYLBUTYL)PHENOXY)ETHOXY)ETHYL)-, CHLORIDE

Systematic Name

English

BENZENEMETHANAMINIUM, N,N-DIMETHYL-N-(2-(2-(3-METHYL-4-(1,1,3,3-TETRAMETHYLBUTYL)PHENOXY)ETHOXY)ETHYL)-, CHLORIDE (1:1)

Systematic Name

English

Classification Tree Code System Code

EPA PESTICIDE CODE

69100